Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have a consensus rating of "Moderate Buy" on Cellebrite (4 buys, 1 sell) with an average 12‑month price target of $22.50; individual actions include Needham cutting its target to $18, Weiss remaining a sell and Wall Street Zen moving to hold.
• In the latest quarter Cellebrite reported $128.82M in revenue (above the $126.07M estimate) and revenue was up 28.8% year‑over‑year, while EPS was $0.14 (in line with estimates); analysts expect 0.43 EPS for the current year.
• The stock trades with a market capitalization of $3.17B, a P/E of 40.97 and a 12‑month range of $11.02–$20.53, and institutional investors now hold about 45.88% after several funds increased their positions.

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

Several analysts have issued reports on the company. Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Wall Street Zen raised Cellebrite DI from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its position in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company's stock valued at $29,000 after purchasing an additional 720 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $40,000. Pacer Advisors Inc. grew its position in shares of Cellebrite DI by 523.4% in the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company's stock valued at $51,000 after purchasing an additional 2,303 shares during the last quarter. Finally, First Horizon Corp grew its position in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company's stock valued at $52,000 after purchasing an additional 2,337 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $12.70 on Monday. The stock's 50 day moving average price is $13.69 and its two-hundred day moving average price is $16.03. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of 40.97, a P/E/G ratio of 1.95 and a beta of 1.28. Cellebrite DI has a 12-month low of $11.02 and a 12-month high of $20.53.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The firm had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. Equities research analysts expect that Cellebrite DI will post 0.43 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.